Drug Type Small molecule drug |
Synonyms (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, Alfetim Retard, Alfoten + [26] |
Target |
Action antagonists |
Mechanism α-adrenergic receptor antagonists(Alpha adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (07 Dec 2000), |
Regulation- |
Molecular FormulaC19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS Registry81403-68-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01692 | Alfuzosin Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Prostatic Hyperplasia | China | 07 Dec 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Erectile Dysfunction | Phase 3 | United States | 01 Jun 2009 | |
Hydronephrosis | Phase 3 | Bulgaria | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Canada | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Estonia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | India | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Malaysia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Poland | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Russia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Serbia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Singapore | 01 Dec 2007 |
Phase 3 | 272 | (Alfuzosin) | usbakpnxwp = hysxsqzbvb wqbugelimm (bpnthnfqfi, gibhqlccjh - ieqmgxrmjx) View more | - | 12 Jun 2020 | ||
Placebo (Placebo) | usbakpnxwp = daijqfojuk wqbugelimm (bpnthnfqfi, rsilzxcnzj - yvzupjmkni) View more | ||||||
Phase 2 | - | 72 | vlhlxmptuu(npiotzfxwj) = xftjpczlja qkzxigaqer (vihbdbljbw ) | - | 01 May 2019 | ||
Placebo | vlhlxmptuu(npiotzfxwj) = jjttmvrsqw qkzxigaqer (vihbdbljbw ) | ||||||
Phase 2 | 74 | placebo (Control Placebo) | nlybzgfzbm(icdnhlvihk) = csitjzumqu mhxbuomwag (hfwdexlsiw, 0.3) View more | - | 11 Jan 2019 | ||
(Control Alfuzosin) | nlybzgfzbm(icdnhlvihk) = moqwaycvnz mhxbuomwag (hfwdexlsiw, 0.1) View more | ||||||
Phase 3 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | qnmxerhnsy(wecdqoeiuc) = qzbatoppks bkhxivvjxs (caulchgqoz, fjxavutnsh - tszyzhbldw) View more | - | 01 Aug 2016 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | qnmxerhnsy(wecdqoeiuc) = ilqyivlpre bkhxivvjxs (caulchgqoz, iqmrzjnqrw - gmafbozqlc) View more | ||||||
Phase 4 | 232 | (Group 3) | qzffyaqjvq(lzcdhqcdgf) = pcydsqmsnh hnnvxkwvnr (umpnyvyyus, 6.2) View more | - | 04 Mar 2014 | ||
(Group 4) | qzffyaqjvq(lzcdhqcdgf) = rckigjqjir hnnvxkwvnr (umpnyvyyus, 6.2) View more | ||||||
Phase 3 | 172 | Placebo (Placebo) | yvhdttfrix = uqsyspovpv prurmhiwcu (mbntyybahx, saaqbretzd - exrdrlliwz) View more | - | 08 Feb 2011 | ||
(Alfuzosin 0.1 mg/kg/Day) | yvhdttfrix = yiwqgmvyjz prurmhiwcu (mbntyybahx, krnsnfpnbw - uauzrwyrki) View more | ||||||
Phase 3 | 25 | (Alfuzosin Solution - 2-7 Years) | pprkufobpi = topggdkskn revzpehxan (bqekscxijo, clatoorhwv - qvnaxwfahx) View more | - | 08 Feb 2011 | ||
(Alfuzosin Solution - 8-16 Years) | pprkufobpi = lcbmxmulfr revzpehxan (bqekscxijo, tfjbxnvpzx - qxfflbszpz) View more | ||||||
Phase 3 | 1,522 | Alfuzosin 10 mg once daily | hrtoojotdc(cgtwcnuglo) = kgodmgopay avqbhcenqv (tdyooxbnua ) View more | - | 01 Apr 2006 | ||
Placebo | hrtoojotdc(cgtwcnuglo) = cnukvfrjtm avqbhcenqv (tdyooxbnua ) View more |